664 related articles for article (PubMed ID: 19222250)
1. Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy.
Cook BA; Warshaw EM
Am J Clin Dermatol; 2009; 10(2):103-18. PubMed ID: 19222250
[TBL] [Abstract][Full Text] [Related]
2. Topical pimecrolimus in the treatment of seborrheic dermatitis.
Brownell I; Quan LT; Hsu S
Dermatol Online J; 2003 Aug; 9(3):13. PubMed ID: 12952760
[TBL] [Abstract][Full Text] [Related]
3. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
4. Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial.
Rigopoulos D; Ioannides D; Kalogeromitros D; Gregoriou S; Katsambas A
Br J Dermatol; 2004 Nov; 151(5):1071-5. PubMed ID: 15541087
[TBL] [Abstract][Full Text] [Related]
5. The role of topical calcineurin inhibitors in atopic dermatitis.
Alomar A; Berth-Jones J; Bos JD; Giannetti A; Reitamo S; Ruzicka T; Stalder JF; Thestrup-Pedersen K;
Br J Dermatol; 2004 Dec; 151 Suppl 70 Dec 2004():3-27. PubMed ID: 15548171
[TBL] [Abstract][Full Text] [Related]
6. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
de Bruin-Weller MS; Bruijnzeel-Koomen CA
Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
[TBL] [Abstract][Full Text] [Related]
8. Topical calcineurin inhibitors for the treatment of vulvar dermatoses.
Goldstein AT; Thaçi D; Luger T
Eur J Obstet Gynecol Reprod Biol; 2009 Sep; 146(1):22-9. PubMed ID: 19631446
[TBL] [Abstract][Full Text] [Related]
9. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study.
Ozden MG; Tekin NS; Ilter N; Ankarali H
Am J Clin Dermatol; 2010; 11(1):51-4. PubMed ID: 20000875
[TBL] [Abstract][Full Text] [Related]
10. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
Wolff K
Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
[TBL] [Abstract][Full Text] [Related]
11. Potential new indications of topical calcineurin inhibitors.
Luger T; Paul C
Dermatology; 2007; 215 Suppl 1():45-54. PubMed ID: 18174692
[TBL] [Abstract][Full Text] [Related]
12. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis.
Tatlican S; Eren C; Oktay B; Eskioglu F; Durmazlar PK
J Dermatolog Treat; 2010 Mar; 21(2):83-5. PubMed ID: 19391059
[TBL] [Abstract][Full Text] [Related]
13. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study.
Cicek D; Kandi B; Bakar S; Turgut D
J Dermatolog Treat; 2009; 20(6):344-9. PubMed ID: 19954391
[TBL] [Abstract][Full Text] [Related]
14. An open-label efficacy pilot study with pimecrolimus cream 1% in adults with facial seborrhoeic dermatitis infected with HIV.
de Moraes AP; de Arruda EA; Vitoriano MA; de Moraes Filho MO; Bezerra FA; de Magalhães Holanda E; de Moraes ME
J Eur Acad Dermatol Venereol; 2007 May; 21(5):596-601. PubMed ID: 17447972
[TBL] [Abstract][Full Text] [Related]
15. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis.
Warshaw EM; Wohlhuter RJ; Liu A; Zeller SA; Wenner RA; Bowers S; Schultz JC; Katz HI; McCormick CL; Parneix-Spake A
J Am Acad Dermatol; 2007 Aug; 57(2):257-64. PubMed ID: 17188780
[TBL] [Abstract][Full Text] [Related]
16. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
18. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
19. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial.
Firooz A; Solhpour A; Gorouhi F; Daneshpazhooh M; Balighi K; Farsinejad K; Rashighi-Firoozabadi M; Dowlati Y
Arch Dermatol; 2006 Aug; 142(8):1066-7. PubMed ID: 16924062
[No Abstract] [Full Text] [Related]
20. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
